University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Jeroen Jansen, PhD

Jeroen Jansen, PhD

Associate Professor, Dept. of Clinical Pharmacy, UCSF

Cancer Center Program Memberships

Cancer Control

Research Summary

Jeroen is a methodologist working at the intersection of evidence synthesis, biostatistics, and health economics.

His current research interests are network meta-analysis and simulation modeling to understand the value of health care interventions, in particular related to oncology and precision medicine. Jeroen has performed applied and methods research in his areas of expertise. Notable contributions are the development of synthesis methods to overcome the typical challenges in cost-effectiveness evaluations characterized by gaps in the evidence base and complex evidence structures. He is a co-author of a textbook on network meta-analysis for decision-making.

Education

Faculty of Human Movement Sciences, Vrije Universiteit, Netherlands, MSc, 1998, Human Movement Sciences
Faculty of Medicine and Health Sciences, Erasmus University, Netherlands, MSc, 2001, Epidemiology
Faculty of Medicine and Health Sciences, Erasmus University, Netherlands, PhD, 2004, Epidemiology

Selected Publications

  1. Keeping ST, Cope S, Chan K, Wilson FR, Jansen JP, Penrod JR, Abraham P, Camidge DR, Korytowsky B, Gu T, Garcia AJ, Le TK, Yuan Y. Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer. J Comp Eff Res. 2020 Nov 03.
    View on PubMed
  2. Incerti D, Hernandez EJM, Tkacz J, Jansen JP, Collier D, Gharaibeh M, Moore-Schiltz L, Stolshek BS. The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis. J Manag Care Spec Pharm. 2020 Oct; 26(10):1236-1242.
    View on PubMed
  3. Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Pre-Infusion Period of Axicabtagene Ciloleucel vs Tisagenlecleucel in Relapsed/Refractory Large B-Cell Lymphoma". Biol Blood Marrow Transplant. 2020 Sep 17.
    View on PubMed
  4. Goulding RE, Chenoweth M, Carter GC, Boye ME, Sheffield KM, John WJ, Leusch MS, Muehlenbein CE, Li L, Jen MH, Rojubally A, Jansen J, Druyts E. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis. Cancer Treat Res Commun. 2020; 24:100200.
    View on PubMed
  5. Thom HZ, Jansen JP, Shafrin J, Zhao LM, Joseph G, Cheng HY, Gupta S, Shah N. . Crizanlizumab and comparators for adults with sickle-cell disease: a systematic review and network meta-analysis. BMJ Open. 2020.
    View on PubMed
  6. Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2020 Sep; 26(9):1581-1588.
    View on PubMed
  7. Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M, Aguiar M, Ponce E, Jansen JP, Ayers D, Goldgrub R. Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. Clinical Kidney Journal. 2020.
    View on PubMed
  8. Jansen JP. Heterogeneity and subgroup analysis in network meta-analysis. In: Ting N, Cappelleri J, Ho S, Chen G. (editors). Design and analysis of subgroups with biopharmaceutical applications. Emerging topics in statistics and biostatistics. Springer, Cham. 2020; 369-385.
    View on PubMed
  9. Cope S, Chan K, Jansen JP. Multivariate network meta-analysis of survival function parameters. Res Synth Methods. 2020 May; 11(3):443-456.
    View on PubMed
  10. Cope S, Toor K, Popoff E, Fonseca R, Landgren O, Mateos MV, Weisel K, Jansen JP. Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. Value Health. 2020 04; 23(4):441-450.
    View on PubMed
  11. Sussell J, Silverstein AR, Goutam P, Incerti D, Kee R, Chen CX, Batty DS, Jansen JP, Kasiske BL. The economic burden of kidney graft failure in the United States. Am J Transplant. 2020 05; 20(5):1323-1333.
    View on PubMed
  12. Jansen JP, Incerti D, Linthicum MT. Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project. Pharmacoeconomics. 2019 11; 37(11):1313-1320.
    View on PubMed
  13. Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8. Adv Ther. 2019 11; 36(11):2982-2985.
    View on PubMed
  14. Cope S, Ayers D, Zhang J, Batt K, Jansen JP. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia. BMC Med Res Methodol. 2019 09 02; 19(1):182.
    View on PubMed
  15. Cope S, Keeping ST, Goldgrub R, Ayers D, Jansen JP, Penrod JR, Korytowsky B, Juarez-Garcia A, Yuan Y. Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer. J Comp Eff Res. 2019 07; 8(10):733-751.
    View on PubMed
  16. Berger KI, Kanters S, Jansen JP, Stewart A, Sparks S, Haack KA, Bolzani A, Siliman G, Hamed A. Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis. J Neurol. 2019 Sep; 266(9):2312-2321.
    View on PubMed
  17. Incerti D, Curtis JR, Shafrin J, Lakdawalla DN, Jansen JP. A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. Pharmacoeconomics. 2019 06; 37(6):829-843.
    View on PubMed
  18. Garrison LP, Jansen JP, Devlin NJ, Griffin S. Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework. Value Health. 2019 06; 22(6S):S12-S17.
    View on PubMed
  19. Incerti D, Thom H, Baio G, Jansen JP. R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment. Value Health. 2019 05; 22(5):575-579.
    View on PubMed
  20. Jansen JP, Incerti D, Curtis JR. Toward Relevant and Credible Cost-Effectiveness Analyses for Value Assessment in the Decentralized U.S. Health Care System. J Manag Care Spec Pharm. 2019 May; 25(5):518-521.
    View on PubMed

Go to UCSF Profiles, powered by CTSI